Early drug development requires adherence to Good Manufacturing Practices (GMP) guidelines when manufacturing investigational medicinal products (IMPs) for clinical studies conducted within Europe. Studies which are directly supported by GMP-compliant on-site manufacturing facilities add substantial value by significantly cutting costs and timelines through proven, efficiency-focused processes.

Register to download

Onsite Manufacturing Early Clinical Development

You may also be interested in: